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Abstract 
Emergent coronary reperfusion therapies are rarely carried out before considerable myocardial 
injury has occurred.  Moreover, reperfusion after prolonged ischemia produces paradoxical 
ischemia-reperfusion injury, attenuating the efficacy of reperfusion therapies.  This has provided 
impetus for identifying chronic therapies to protect against ischemia-reperfusion injury in those at 
risk.  We previously found regular dipyridamole therapy produces a chronic preconditioning-like 
effect mediated through adenosine A1 receptors. To determine how long this chronic 
preconditioning effect of dipyridamole remains present after discontinuing therapy, guinea pigs 
received 4 mg/kg/day in their water for 6 weeks. Ischemia-reperfusion was performed at 0, 2, 3, and 
4 days after dipyridamole discontinuation (0Day, 2Days, 3Days and 4Days; n=8 per group).  Left 
ventricular developed pressure (LVDP), end-diastolic pressure (LVED), coronary flow (CF), infarct 
size, and western blot analyses for Akt and endothelial nitric oxide synthase (eNOS) were studied. 
After ischemia-reperfusion, 0Day, 2Days and 3Days, but not 4Days, had significantly higher LVDP 
and lower LVDEP compared to control. Myocardial infarct size was significantly reduced at 0Day, 
2Days and 3Days, but not 4Days, compared to control. Western blot analyses demonstrated 
upregulation of phospho-Akt and phospho-eNOS expression at 0Day, 2Days, 3Days, but not 4Days. 
A chronic preconditioning-like cardioprotection by regular dipyridamole treatment persists for 3 
days after discontinuing therapy. Increased activated Akt and eNOS expression may play a role in 
this persistent cardioprotection.  
 
The Persantine-Aspirin Reinfarction Study (PARIS) Research Group examined the efficacy of 
Persantine (dipyridamole 75 mg) in combination with aspirin (324 mg) versus aspirin alone or 
placebo for preventing reinfarction in 2026 patients with a prior history of myocardial infarction in 
the preceding 8 weeks to 5 years[1]. No significant differences were observed between 
dipyridamole plus aspirin versus aspirin alone in total mortality, coronary mortality, or nonfatal 
myocardial infarction (MI). However, patients were followed from 1975 to 1979, before 
revascularization procedures were widely available. Follow up studies and meta-analyses also 
supported the lack of benefit of adding dipyridamole to aspirin to prevent cardiovascular events, 
with the possible exception of strokes in at risk patients.  
 
Acute MI’s are now routinely treated with emergent reperfusion therapies. However, these 
reperfusion therapies are rarely carried out before considerable myocardial injury has occurred.  
Moreover, reperfusion after prolonged ischemia produces a paradoxical ischemia-reperfusion 
injury[2,3], potentially attenuating the efficacy of reperfusion therapies.  This has provided 
impetus for identifying therapies which protect against ischemia-reperfusion injury.  Acute 
interventions, including ischemic preconditioning and infusion of adenosinergic agents (including 
dipyridamole)[2-4], reduce ischemia-reperfusion injury in animal models and human myocardium.  
To date, continual protection against ischemia-reperfusion injury is not available for patients at high 
risk for MI who may require emergent reperfusion therapy.   
 
Several lines of evidence suggest that nucleoside transport inhibitors, which increase extracellular 
adenosine levels by inhibiting uptake into myocytes and endothelial cells, might offer sustained or 
chronic protection against ischemia-reperfusion injury.  We previously demonstrated that chronic 
exposure to ethanol, an adenosine uptake inhibitor, reduces ischemia-reperfusion injury in guinea 
pig hearts, requiring adenosine A1 receptor signaling and εPKC translocation within the myocyte to 
effect cardioprotection[5,6]. While mechanistically interesting, the search for a safer therapy against 
ischemia-reperfusion injury was necessary. We subsequently found that regular dipyridamole 
therapy, a clinically usable nucleoside transport inhibitor, induces similar continual cardioprotection 
to that seen with chronic ethanol exposure, also mediated through adenosine A1 receptor 
activation[7].   
 
As dipyridamole is clinically available, we asked whether chronic therapy with this adenosine 
uptake inhibitor produces continued protection against ischemia-reperfusion injury that lasted 
beyond 24 hours after the last dosing. We further sought to identify potential mechanisms 
underlying this sustained cardioprotective effect.  We found that regular dipyridamole therapy 
protects against ischemia-reperfusion injury, a protective effect persisting for at least 3 days 
following the last dosing. This sustained protection was associated with continued increased 
expression of activated Akt and endothelial nitric oxide synthase (eNOS), known mediators of 
myocyte preconditioning signaling cascades.   
Materials and Methods  
This study was conducted in accordance with the Guidelines for Animal Research at Osaka 
Dental University, and with the approval of the Animal Experiment Committee of Osaka Dental 
University, Osaka, Japan. These guidelines conform with the Guide for the Care and Use of 
Laboratory Animals from the National Academy of Sciences, Washington D.C, USA. Male Hartley 
guinea pigs were fed Lab Diet (RC4, Oriental Yeast, Tokyo, Japan) and given water ad libitum. 
Dipyridamole was added to the drinking water of the dipyridamole-treated guinea pigs (11.4 mg/l) 
for 6 weeks. Guinea pigs drink approximately 3.5 ml water per 10 g of body weight per day, 
resulting in a dipyridamole intake of 4mg/kg/day. This dose approximates the daily human dose of 
75–100 mg four times daily. A diagram of the experimental protocol is shown in Figure 1. 
 
Isolated Heart Perfusion and Measurement of Function 
Male guinea pigs weighing 550-700g (12-13 weeks old) were given heparin (1000 units 
intraperitoneally), then anesthetized with pentobarbital (60 mg/kg, intraperitoneally). Hearts were 
excised and immediately arrested in cold iso-osmotic saline containing 20 mM KCl. The aorta was 
cannulated and the isolated hearts were perfused at 70 mmHg on a nonrecirculating isovolumic 
perfused heart apparatus, using a Krebs-Henseleit perfusate and paced at 240 beats/min as 
previously described.[5]  Left ventricular developed pressure (LVDP; mmHg) was measured 
using a 2.5 French, high-fidelity micromanometer (Nihon-Kohden, Tokyo, Japan) passed into a 
compliant latex balloon, inserted into the left ventricle, and recorded on a PowerLab 2/20 Data 
Recording System (ADInstruments, Hayward, Australia). The balloon was connected to a 
Y-adapter with one end used to advance the micromanometer and the other used to fill the left 
ventricular balloon with bubble-free water to an end-diastolic pressure (LVEDP) of 10 mmHg. 
Coronary flow (CF) (ml/min) was measured by collecting effluent. Global ischemia was achieved 
by clamping the aortic inflow line. During ischemia, hearts were maintained at 37 °C by enclosure 
in a water-jacketed air chamber. Warmed perfusate kept in the lower part of the chamber saturated 
the air with humidity and prevented cooling by evaporation. Heart temperature was continuously 
monitored by a digital thermometer (PTW-100A, Unique Medical, Tokyo, Japan).  
 
Experimental Protocol 
Forty guinea pigs were divided into 5 groups of eight each (see Figure 1). After a 20 min 
equilibration, baseline LVDP, LVEDP and CF were recorded. Eight hearts were subjected to 30 
min of ischemia followed by 120 min of reperfusion (control; CTL). Ischemia-reperfusion was 
performed at 0, 2, 3, and 4 days after discontinuation of dipyridamole in four additional groups of 
eight each (0Day, 2Days, 3Days and 4Days).    
 
Determination of Myocardial Infarct Size 
At the end of experiments, hearts were quickly frozen at –80 °C for 15 min, and then sliced 
into 2 mm thick transverse sections from apex to base (6 slices/heart). After removing the right 
ventricle and defrosting, each slice was weighed and incubated at 37 °C with 1% 
triphenyltetrazolium chloride (Sigma Chemicals) in phosphate buffer (pH 7.4) for 10 min and then 
fixed in 10% formalin for at least 5 h to distinguish red stained viable tissue from pale unstained 
necrotic tissue.[8] Each slice was photographed and the necrotic area was determined using Adobe 
Photoshop® CS (Adobe, San Jose, CA, USA) and multiplied by the weight of the slice, then 
expressed as a fraction of the left ventricle.  
 
Western Blot Analysis 
     Separate experiments were performed on eight additional hearts to examine expression of Akt 
and eNOS (n=4 for each group). Myocardial tissue samples were collected after 120min reperfusion, 
and homogenized in ice-cold homogenizing buffer containing 250 mM sucrose, 20 mM HEPES (pH 
7.5), 10 mM KCl, 2 mM EGTA, 2 mM MgCl2, 25 mM NaF, 50 mM β-glycerophosphate, 1 mM 
Na3VO4, 1mM PMSF and protease inhibitor leupeptin (10 µg/ml). The homogenate was centrifuged 
at 1000g for 5 min at 4 °C to clean up. The supernatant was re-centrifuged at 10000g for 15 min at 4 
°C to obtain cytosolic fraction. The protein concentration was estimated with a Bradford assay. 
Equivalent amounts (20 µg) of protein samples were loaded and separated on a 10% SDS-PAGE 
gradient gel, then electrically transferred overnight to a polyvinylidene difluoride membrane 
(Bio-Rad, Hercules, CA, USA). After blocking with 5% skim milk in Tris-buffered saline containing 
0.1% Tween-20 (TBS-T), the membranes were incubated for 2 h at 4 °C in TBS-T containing 5% 
skim milk and overnight 1:1000 dilution of rabbit primary antibody for phospho-Akt (Ser437; Cell 
Signaling Technology, Boston, MA), and phospho-eNOS (Ser177; Cell Signaling Technology, 
Boston, MA). Membranes were incubated with a 1:1000 dilution of horseradish peroxidase–labeled 
anti-rabbit immunoglobulin G (NA 934V, GE Healthcare, Buckinghamshire, United Kingdom). The 
same blot was stripped and re-blotted with antibodies to total-Akt, total-eNOS (Cell Signaling 
Technology, Boston, MA) and α -tubulin (Santa Cruz Biotechnology) to confirm equal protein 
loading. Bound antibody signals were detected with enhanced chemiluminescence (Pierce 
Biotechnology, Rockford, IL) and visualized using VersaDoc 5000 Imaging System (Bio-Rad, 
Hercules, CA, USA). Quantitative analysis of the band densities was performed by Quantity One 
software (Bio-Rad), and the results are presented as the ratio of phospho-Akt and phospho-eNOS to 
total Akt and eNOS. The average light intensity was multiplied by 100 to facilitate presentation of an 
x-fold increase.  
 
 
Statistical Analysis 
 
All data are expressed as mean±SD. Statistical power analysis revealed that a sample size of 
n=8 per group would provide sufficient power (0.8) to detect a difference between mean infarct size 
indices of 15 % (SD=9, α=0.05). A group size of n=4 was used for Western blot to provide a power 
of 0.8 to detect a difference between means of 20% (SD=10, α=0.05). Hemodynamic data were 
tested for normal distribution and subsequently analyzed by a two-factor repeated-measures 
analysis of variance for time and treatment. If an overall difference between the variables was 
observed, comparisons were performed as one-way ANOVA followed by Tukey's post-hoc test for 
inter-group differences and by Dunnett's for intra-group differences with baseline values as the 
reference time point. Analyses of infarct size and Western blot were performed using one-way 
ANOVA followed by Student's t-test with Bonferroni's correction for multiple comparisons to 
avoid type I error. For changes within and between groups a two-tailed p value less than 0.05 was 
considered significant in advance. (SPSS17 for Windows, SPSS Japan, Tokyo, Japan).  
 
RESULTS 
 
Regular Dipyridamole Therapy Improves Contractile Recovery During Post-Ischemic Reperfusion.  
Baseline LVDP, LVEDP and coronary flow were similar in perfused hearts from animals treated for 
six weeks with dipyridamole and age-matched controls (Table 1).  LVDP recovery was 
significantly improved during post-ischemic reperfusion in hearts from animals treated with 
dipyridamole for 6 weeks compared to controls at 0Day, 2Days, 3Days, but not 4Days (51±14 
mmHg, 49±15 mmHg, 54±10 mmHg, 43±10 mmHg at 0Day, 2Days, 3Days and 4Days versus 27±6 
mmHg in controls, p<0.05 for 0Day, 2Days, 3Days; Table 1). LVEDP rise, an indicator of 
myocardial contracture, was lower in hearts from dipyridamole-treated animals compared to 
controls at 0Day, 2Days, 3Days, but not 4Days (23±13 mmHg, 23±10 mmHg, 26±18 mmHg, 
35±11 mmHg at 0Day, 2Days, 3Days and 4Days versus 52±24 mmHg in controls, p<0.05 for 0Day, 
2Days, and 3Days; Table 1). These data suggest that dipyridamole therapy for 6 weeks improved 
contractile recovery and reduced the degree of contracture or irreversible myocardial injury after 
ischemia-reperfusion for at least 3 days after discontinuation of therapy. There were no differences 
in coronary flow or coronary perfusion pressure before or after ischemia-reperfusion in 
dipyridamole versus control hearts (Table 1).  This suggests that differences in coronary flow 
cannot account for the improved contractile recovery after ischemia-reperfusion in hearts from 
animals chronically treated with dipyridamole.  
 
Regular Dipyridamole Therapy Reduces Infarct Size.  Myocardial infarct size data are 
shown in Figure 2. Myocardial infarct size in hearts from animals treated with dipyridamole were 
significantly reduced by approximately 50% compared with control hearts at 0Day, 2Days, and 
3Days, but not 4Days (22±12 %, 22±5 %, 22±6 %, 37±8 % at 0Day, 2Days, 3Days and 4Days 
versus 42±5 %, controls, p<0.05 for 0Day, 2Days, and 3Days; Table 1).  
   
Cardioprotection by Dipyridamole Persists After Discontinuation of Treatment:  The effects of 
discontinuing regular dipyridamole therapy on contractile recovery and infarct size after 
ischemia-reperfusion are shown in Table 1 and Figure 2. Cardioprotection from chronic 
dipyridamole treatment persisted for at least three days after discontinuation of treatment. By the 
fourth day this cardioprotection began to dissipate, as evidenced by a non-significant improvement 
in contractile functional recovery (LVEDP) and infarct size. 
 
Persistent Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury is Associated 
with Activated Akt and eNOS Expression:  As shown in Figure 3, expression of activated Akt and 
activated eNOS were elevated in hearts from dipyridamole-treated animals when compared to 
control hearts. These increased expressions of activated Akt and activated eNOS persisted for at 
least three days after discontinuation of dipyridamole treatment. These persistent expressions of 
potential preconditioning mediators coincided with the time course after discontinuation of 
dipyridamole treatment of decreased infarct size and improved hemodynamics following 
ischemia-reperfusion. 
 
DISCUSSION 
 
The major finding of this study is that regular dipyridamole therapy produces sustained or chronic 
protection against ischemia-reperfusion injury in guinea pig hearts that persists for at least 3 days 
after discontinuing treatment. Furthermore, increased activated Akt and activated eNOS expression 
coincide with this persistent cardioprotection and may play a role in mediating this chronic 
preconditioning-like effect. There is currently no therapy available to induce chronic 
cardioprotection against ischemia-reperfusion injury in patients at high risk for MI who may require 
emergent reperfusion therapy.  Understanding the mechanisms underlying this persistent 
cardioprotective effect of regular dipyridamole treatment may help in the development of therapies 
to protect these at risk patients. 
 
Acute dipyridamole therapy mimics ischemic preconditioning and has been shown to enhance the 
protective effect of preconditioning against ischemia-reperfusion injury[9].  Acute exposure to 
other nucleoside transport inhibitors, including dilazep[10] and ethanol[11], also mimic or enhance 
the protective effect of ischemic preconditioning against ischemia-reperfusion injury.    
 
We previously demonstrated that regular exposure to ethanol (daily for as little as 3 weeks), an 
adenosine uptake inhibitor[12], produced sustained cardioprotection against ischemia-reperfusion 
injury[5,6].  This preconditioning-like effect of regular ethanol treatment was attenuated in the 
presence of selective adenosine A1 receptor antagonism[5].  Further, this ethanol-induced 
cardioprotection persisted for at least seven days after discontinuing ethanol consumption[13]. 
Interestingly, epidemiological data are consistent with these observations; regular drinkers have 
improved outcomes after acute MI when compared to abstainers[14,15].  Unfortunately, it is not 
safe to recommend the cardioprotective effects of ethanol consumption given the risks for abuse and 
alcoholic-related diseases.  Furthermore, ethanol, no doubt, has pleotropic effects beyond its 
inhibition of adenosine reuptake, which may have detrimental effects on the heart, especially with 
heavy consumption.  Therefore, we sought to determine whether regular dipyridamole therapy, a 
safer adenosine uptake inhibitor, produced a similar chronic preconditioning-like effect[7].   
 
Although the potential benefits of regular dipyridamole therapy in protecting against 
ischemia-reperfusion injury have not been examined clinically, dipyridamole has been already 
studied as potential therapy to reduce the risk of re-infarction in patients after MI[1].  In the 
Persantine-Aspirin Reinfarction Study (PARIS), the efficacy of the combination of dipyridamole 
and aspirin, aspirin alone, or placebo in preventing subsequent cardiac events in patients who had 
previously suffered an MI was examined[1].  Dipyridamole and aspirin produced no statistically 
significant additional benefit on total mortality, coronary mortality, or nonfatal MI compared to 
aspirin alone (subgroup analysis did show that subjects less than 6 months from their previous MI 
benefited from combination therapy). However, the PARIS trial was performed in the 
pre-thrombolytic era.  In this era of emergent reperfusion therapies, potential chronic 
preconditioning therapies require re-examination. 
 
No therapy is yet available which produces a sustained preconditioned state.  Cohen and 
colleagues reported that the cardioprotective effect of ischemic preconditioning in rabbits (40 to 65 
five min occlusive episodes) waned after 3 to 4 days[16].  Dana et al., demonstrated that a 
preconditioned state could be maintained in rabbits for at least 10 days using intermittent, not 
continuous, infusion of an adenosine A1 agonist 2-chloro-N6-cyclopentyladenosine (CCPA)[17].  
While activation of cardioprotection by regular dipyridamole therapy, intermittent CCPA or acute 
ischemic preconditioning may be mediated similarly at the time of ischemia (e.g., via adenosine A1 
receptor activation), chronic dipyridamole therapy may induce more lasting responses that produce 
sustained protection which are not maintained by continued ischemic preconditioning.  For 
example, we found that chronic exposure to ethanol causes sustained translocation and activation of 
epsilon protein kinase C (εPKC) in myocytes[6], a PKC isozyme implicated in ischemic 
preconditioning[18].  When regular treatment with an adenosine uptake inhibitor produces 
sustained εPKC translocation to its site of activation[6], and εPKC is then triggered by the 
adenosine A1 receptor signaling cascade at the time of ischemia, εPKC is already primed to open 
sarcolemmal and mitochondrial adenosine triphosphate-sensitive potassium channels (mitoKATP), 
shown to play a role in reducing infarct size in ischemic and ethanol preconditioning[11].   
 
Cardiac myocytes express eNOS which regulates myocardial contractile function and oxygen 
consumption[19]. Nitric oxide is an important mediator in cardioprotection, activating mitoKATP[20]. 
Knockout mice lacking eNOS suffer larger infarcts than wild type after ischemia[21]. 
Overexpression of eNOS in mice attenuates myocardial ischemia-reperfusion injury[22]. In our 
study, increased activated eNOS expression coincided with the persistent dipyidamole-induced 
cardioprotection for at least three days after discontinuation of therapy. We previously reported on 
persistent cardioprotection by chronic ethanol consumption after abstention and the potential role of 
activated eNOS in that persistent cardioprotection model[13].  
 
Preventing mPTP opening by inhibiting glycogen synthase kinase 3β  (GSK-3β ) has been shown to 
play a role in ischemic preconditioning[24]. Irreversible mPTP opening abolishes the mitochondrial 
membrane potential, disabling ATP production. GSK-3 β  is a substrate for multiple pro-survival 
protein kinases, including Akt. Inhibiting GSK-3 β  by PI3/Akt signaling is a key event in preventing 
mPTP opening, increasing cell survival[25]. Zhong et al., reported that mice fed 18% ethanol in 
their drinking water for 12 weeks demonstrated sustained translocation of ε -PKC, as well as 
increased Akt expression[26]. In our study, increased activated Akt expression coincided with 
persistent dipyidamole-induced cardioprotection for at least three days after discontinuation of 
therapy. 
 
There is currently no therapy available to induce sustained protection against ischemia-reperfusion 
injury in patients at high risk for MI who may require emergent reperfusion therapy.  Our data 
suggest that regular dipyridamole therapy produces sustained protection against 
ischemia-reperfusion injury, lasting up to three days after discontinuation of treatment.  
Furthermore, increased activated Akt and activated eNOS expression coincide with this persistent 
cardioprotection and may play a role in mediating this chronic preconditioning-like effect. Future 
studies will determine how chronic exposure to adenosine uptake inhibitors produce this delayed, 
yet sustained, preconditioning state. 
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FIGURE LEGENDS 
 
Figure 1. Schematic illustration of experimental protocol. All hearts were subjected to 30 min of 
global ischemia followed by 120 min of reperfusion. Dipyridamole-treated guinea pigs received 4 
mg/kg/day dipyridamole in their drinking water for 6 weeks. Ischemia-reperfusion was performed at 
0, 2, 3, and 4 days after discontinuation of dipyridamole (0Day, 2Days, 3Days and 4Days; n=8 for 
each group). Tissue samples were obtained at baseline and 120 min after reperfusion (n=4 for each 
group).   
 
Figure 2. Infarct size as a percentage of the left ventricle. Myocardial infarct size was significantly 
reduced in 0Day, 2Days and 3Days, but not 4Days, compared to control (22±12%, 21±5%, 22±6%, 
37±8% at 0Day, 2Days, 3Days and 4Days versus control 42±5%, * p<0.05 for 0Day, 2Days, 
3Days; n=8 for each group). 
 
Figure 3. Western blot analyses of inducible endothelial nitric oxide synthase (eNOS) and Akt from 
left ventricular samples in hearts from control and dipyridamole-treated animals. In the 
dipyridamole group (except 4Days), expression of activated eNOS and Akt were significantly 
increased compared with control at baseline (A) and after 120 min reperfusion (B). Data are 
presented as mean±SD. * p<0.05 vs. CTL, n=4 for each group 
 
Table 1.  
Data are presented as mean±SD. * p<0.05 vs. CTL n=8 each group 
LVDP = left ventricular developed pressure; LVEDP = left ventricular end-diastolic pressure; CF = 
coronary flow 
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